Ozempic Builds No Muscle—DEXA Numbers Prove It

If you're on Ozempic, Wegovy, or tirzepatide and the number on your scale is dropping, something real is happening. The question DEXA data keeps forcing us to ask is: what exactly is that something?

Here's the short answer, grounded in the numbers we see at Kalos across hundreds of scans on GLP-1 users in the Bay Area: GLP-1 medications do not build muscle. They were never designed to. And when weight loss happens fast—without a deliberate, data-monitored plan to protect lean mass—muscle goes with the fat. Sometimes more muscle than fat.

This isn't a reason to stop your medication. It's a reason to measure what your medication is actually doing to your body composition, not just your body weight.

How Does a GLP-1 Work in the Body?

To understand what GLP-1 drugs do and don't do for your body composition, it helps to understand how GLP-1 works in the body.

GLP-1—glucagon-like peptide-1—is a hormone your gut naturally produces in response to eating. It signals your pancreas to release insulin, tells your liver to slow glucose production, and critically, sends satiety signals to your brain. You feel full faster. You stay full longer. Appetite drops substantially.

That's the mechanism. Ozempic and Wegovy (semaglutide) mimic and extend this effect. Tirzepatide (Mounjaro, Zepbound) adds a second hormone agonist—GIP—which amplifies the response further. The clinical result is a significant reduction in caloric intake without requiring conscious willpower.

What GLP-1 receptor agonists do not do is tell your body which tissue to break down for energy. That decision is driven by your protein intake, your resistance training stimulus, your sleep quality, and your overall training volume. The medication creates a caloric deficit. Your body then decides how to fill that deficit—from fat, from muscle, or from both.

Without intervention, the research is consistent: the body takes the path of least resistance. And lean mass is frequently part of that path.

What DEXA Scans Show GLP-1 Users

When someone walks into Kalos after three to six months on a GLP-1 medication, the scan tells a story the scale never could.

We regularly see members who have lost 20, 30, even 40 pounds. On the surface, that looks like a win. But when we break the DEXA data down into fat mass versus lean mass, a pattern emerges that concerns our coaches every time:

• Fat mass is down—often meaningfully.
• Lean mass is also down—sometimes by as much as 30–40% of total weight lost.
• Visceral adipose tissue (VAT) has decreased, which is genuinely positive.
• Appendicular lean mass index (ALMI)—the clinical marker for muscle sufficiency in the limbs—has dropped toward or below age-adjusted thresholds.
• Bone mineral density (BMD) shows early warning signs in longer-duration users who weren't resistance training.

The third bullet is the one that gets dismissed. People see lower visceral fat and feel validated. But ALMI declining toward sarcopenic range is a different kind of problem—one that doesn't show up on any standard medical panel, any wearable, or any scale. It only shows up on a DEXA scan.

This is exactly the education gap Kalos exists to fill. If you're curious about losing weight on GLP-1s without destroying your muscle, the data-driven approach starts with knowing your baseline numbers before assumptions take over.

The 67% Problem

Clinical trials on semaglutide and tirzepatide consistently show that somewhere between 25% and 40% of weight lost on GLP-1 medications is lean mass—not fat. Some studies in older adults or people who weren't resistance training push that number higher.

At Kalos, when we look at our GLP-1 member scans without structured coaching in place, we see something in that range. When coaching, protein targets, and resistance training are part of the plan from day one, lean mass retention improves dramatically—and in some cases, members simultaneously lose fat and gain muscle while on the medication.

That second outcome—fat loss plus muscle gain—is body recomposition. It doesn't happen by accident on GLP-1s. It requires deliberate programming, sufficient protein, and regular measurement to confirm the plan is actually working. If you're wondering why Ozempic seems to have stopped working, muscle loss and a declining resting metabolic rate are the two most likely culprits—and only a DEXA scan can tell you which one is driving the plateau.

GLP-1 and Muscle Loss: The Mechanism

The connection between GLP-1 and muscle loss isn't a side effect listed on the package insert. It's a downstream consequence of how aggressive caloric restriction interacts with muscle protein synthesis.

Here's what's happening physiologically:

1. Appetite suppression reduces protein intake. GLP-1 medications don't selectively suppress appetite for fat and carbohydrates. They reduce overall food intake. Many users end up eating 800–1,200 calories per day without intending to—and without consuming anywhere near adequate protein. When protein intake drops below ~1.6–2.2 grams per kilogram of body weight (the range most sports science supports for lean mass preservation during a deficit), muscle becomes a fuel source.

2. Muscle protein synthesis slows in a large deficit. Deep caloric restriction—even with adequate protein—blunts the anabolic signaling that rebuilds and maintains muscle. The body down-regulates mTOR activity. Without a resistance training stimulus to counter this signal, muscle atrophy accelerates.

3. Reduced training volume compounds the problem. Many GLP-1 users report fatigue and nausea, especially in the first months. Training frequency drops. And without the mechanical load that tells muscle fibers to stay, they don't.

4. Metabolic adaptation follows. As lean mass declines, resting metabolic rate (RMR) declines with it. This is the mechanism behind the dreaded plateau—and it's precisely what scans of Ozempic users reveal when fat loss stops matching weight loss.

None of this is unique to GLP-1 medications. Any aggressive caloric deficit without structured resistance training and adequate protein produces the same result. GLP-1 drugs make the deficit so easy to achieve—and so deep—that the muscle loss accelerates faster than most users realize.

What "Weight Loss" Actually Looks Like on a DEXA Report

A DEXA scan doesn't give you a single number. It gives you a breakdown of every pound—where it came from and what kind of tissue it represents. When a GLP-1 user comes in for a scan at Kalos, here's the kind of data our coaches work through:

• Total body fat mass (lbs and %) — Is the fat percentage actually decreasing, or is lean mass loss making the composition look worse relative to bodyweight?
• Total lean mass (lbs) — Has it declined? By how much? Which regions?
• Regional lean mass — Arms and legs (appendicular lean mass) are the most functionally important for long-term independence and metabolic health. Losing lean mass here is a red flag.
• Visceral adipose tissue (VAT) score — This is the metabolically dangerous fat surrounding your organs. GLP-1s do tend to reduce VAT, which is one of their genuine benefits.
• Bone mineral density (BMD) — Extended periods of low protein intake and reduced mechanical loading can accelerate bone loss, especially in women over 40. This is something most GLP-1 prescribers never check.
• ALMI (Appendicular Lean Mass Index) — Normalized for height, this is the clinical diagnostic for sarcopenia risk. It's the number that tells you whether your muscle mass is sufficient for your age and frame—not just whether it's "less than before."

A scale gives you one data point. A DEXA report gives you the full picture. They often tell completely different stories. This is the core problem Kalos was built to solve: the fitness industry has a description problem. Without gold-standard metrics, you're guessing. For more on why the scale misleads even when you're doing everything right, see muscle versus scale weight—what matters more after 40.

The Three Things GLP-1 Users Need That Ozempic Can't Provide

GLP-1 medications create the conditions for weight loss. They do not create the conditions for body composition improvement. Those are different goals, and they require different tools.

Based on what our coaches see in scan data, GLP-1 users need three things their prescription doesn't come with:

1. A Protein Floor, Not a Protein Target

Most GLP-1 users are told to "eat protein." Almost none are told exactly how much—calibrated to their current lean mass, their rate of weight loss, and their training volume. This is where Kalos's nutrition framework applies directly: quantity comes first, and for GLP-1 users in a deficit, protein quantity is the variable with the highest leverage on lean mass retention.

Our coaches set a protein floor based on DEXA-measured lean mass—not estimated body weight, not BMI. The difference matters. Someone with high body fat and lower lean mass needs a meaningfully different protein target than someone of the same weight with higher muscle mass.

2. Resistance Training—Not Just Movement

Walking, yoga, and light cardio do not prevent muscle loss in a significant caloric deficit. Resistance training—specifically, progressive overload with sufficient intensity—sends the mechanical signal that tells your body to preserve muscle tissue even when energy is restricted.

This is the 80% factor in the exercise framework: consistency. Are you resistance training? Yes or no. The specific program matters less than the stimulus existing at all. GLP-1 users who add structured resistance training to their protocol preserve meaningfully more lean mass, and our scan data confirms it.

3. Monthly Measurement—Not Annual Weigh-Ins

A GLP-1 medication changes your body composition faster than any other intervention most people will ever use. That speed is an argument for more frequent measurement, not less. At Kalos, members on GLP-1s come in monthly. If a scan shows lean mass declining faster than fat mass, we adjust the plan immediately—before the metabolic damage compounds.

This is the prescription problem the broader health industry fails to solve. Good data without a feedback loop isn't useful. Monthly DEXA scans with coached interpretation close that loop. If you're weighing whether it's worth retesting, here's what 60-day retests actually reveal about whether your plan is working.

Who Is Most at Risk of GLP-1-Related Muscle Loss?

Not every GLP-1 user experiences the same degree of lean mass loss. Our scan data suggests the highest-risk profiles are:

• Adults over 45, particularly women, who are already in the natural decline phase of muscle mass (sarcopenia begins in the fourth decade and accelerates). For this group, GLP-1-driven muscle loss compounds a trend that was already moving in the wrong direction. The numbers on lean mass loss after 50 are worth understanding before starting any aggressive weight loss protocol.
• People with low baseline lean mass—particularly those in the "skinny fat" category who appear normal weight but carry excess fat and insufficient muscle. For this group, the starting point is already problematic, and any further lean mass loss accelerates metabolic and functional risk.
• Users who aren't resistance training at all. This is the single most predictive behavioral factor. The scan data on sedentary GLP-1 users versus those doing structured resistance training looks dramatically different within six months.
• High-rate losers—people losing more than 1–1.5 lbs per week consistently. Faster weight loss correlates with a higher proportion of lean mass in that loss. The medication makes rapid weight loss easy to achieve without intending to.

If you're over 45 and thinking about GLP-1 medications, the case for tracking sarcopenia risk before symptoms appear is particularly strong. By the time functional decline is noticeable, lean mass has already dropped significantly.

Where to Get a DEXA Scan Near You in the Bay Area

If you're looking for where to get a DEXA scan near you in the Bay Area, Kalos has three locations: San Francisco, Palo Alto, and San Jose (Pruneyard).

All scans are HSA/FSA eligible. Every scan is followed by a 30-minute in-person analysis with an NASM-certified performance analyst—not a printout handed to you at the front desk. The analysis session is where your numbers get translated into an actual plan: what your lean mass, fat mass, VAT score, and ALMI mean for your health right now, and what needs to change.

For GLP-1 users specifically, we recommend scanning before you start or as early in your protocol as possible to establish a true baseline. Every subsequent scan then answers the question that actually matters: is your medication working for your body composition—or just for your scale?

Over 3,000 scans completed. 4.9 stars on Google across 500+ reviews. The scan is the entry point. The transformation is what follows.

The Bottom Line

Ozempic will not build your muscle. The data is unambiguous on this. What it will do—reliably, powerfully—is create the caloric conditions under which muscle loss becomes likely if you aren't actively working against it.

The people who come out of a GLP-1 protocol with better body composition than they started with—more muscle, less fat, lower visceral fat, preserved bone density—are the people who measured their starting point, monitored their progress monthly, hit a protein floor consistently, and kept resistance training even when the medication made them less hungry and more fatigued.

That's not a complicated protocol. But it requires data to execute correctly, and it requires someone who can read that data and adjust the plan when the numbers move in the wrong direction.

If you're on a GLP-1 medication and you don't yet know your ALMI, your lean mass trend, or your visceral fat score—the most important number your scale will never tell you—that's the gap worth closing first.